Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Novocure (NASDAQ: NVCR) stock down 37% - the analysts know nothing either

A reminder that stock market analysts are perhaps slightly better informed than we are but by no means always right

Update : 29 Aug 2023, 02:04 PM

Novocure (NASDAQ: NVCR) stock is down 37%. NVCR stock fell on the admission that its ovarian cancer treatment does not, umm, work. Well, this happens in medical trials, this is why we have medical trials, to find out what works. The thing is that only a few weeks back we were all told to stock up on Novocore stock because the rewards, as compared to the risk, looked very good indeed. As we can see that turned out not to be - but this is a more important point than just to say Har, Har. Reality is a difficult and complex place. The analysts, the stockbrokers, advisors, they’re all fighting through the same fog of not enough information as the rest of us. They might be right more often than we are but that’s all it is, more often, not always.

As to what happened at Novocore:  “Novocure (NVCR.O) said on Monday its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer, dragging shares of the company down to a five-year low. A separate trial in June in a type of lung cancer patients raised concerns about the commercial success of the device, which in combination with certain chemotherapies and immunotherapies helps in creating electric fields that disrupt cancer cell growth.” Perhaps one of those interesting ideas that does not actually work in the complexity of the human body. As we say, this is why trials are done, to find out.

Novocore stock price from Google Finance

The amusement part here - or the educational part if you wish - is that a few weeks back Piper Sandler was telling us all to stock up on Novocore: “Fintel reports that on August 8, 2023, Piper Sandler upgraded their outlook for NovoCure (NASDAQ:NVCR) from Neutral to Overweight . Analyst Price Forecast Suggests 222.70% Upside. As of August 2, 2023, the average one-year price target for NovoCure is 86.87. The forecasts range from a low of 33.33 to a high of $210.00. The average price target represents an increase of 222.70% from its latest reported closing price of 26.92.” So, that all worked out well then.

There is an important point here though, over and above simply laughing. Which is that the analysts are, as we say, fighting through that fog of not enough information just as we are. They know more than we do, sure they do - their decisions and valuations contain more information than ours do. And yet they’re not right all the time. The world is simply far too complex for that. 

The lesson to take from this is that analyst recommendations are just another information input into our own decisions, not rigid insistences as to the truth. Novocore stock is, only weeks later, at half the lowest price target the assembled investment banking community told us it was going to be. And note that it’s our money that would have been lost, not that of the analysts, if we’d believed them.

Top Brokers